Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

O Garraud, F Heshmati, B Pozzetto, F Lefrere, R Girot, A Saillol, S Laperche, O Garraud, F Heshmati, B Pozzetto, F Lefrere, R Girot, A Saillol, S Laperche

Abstract

Plasma therapy consists in bringing to a patient in need - in general suffering a severe, resistant to current therapy, and even lethal infection - plasma or specific, fractioned, antibodies, along with other immunoglobulins and possibly healing factors that can be obtained from immunized blood donors; donors (voluntary and benevolent) can be either actively immunized individuals or convalescent persons. Plasma therapy has been used since the Spanish flu in 1917-1918, and regularly then when viral epidemics threatened vulnerable populations, the last reported occurrence being the 2013-2015 Ebola virus outbreak in West Africa. The precise action mechanism of plasma therapy is not fully delineated as it may function beyond purified, neutralizing antibodies.

Keywords: Anticorps neutralisants; Convalescent plasma; Ebolavirus; Ebolavirus infection; Infectious disease; Maladies infectieuses; Neutralizing antibodies; Plasma convalescent; Plasma therapy; Plasma thérapeutique; Plasmathérapie; Therapeutic plasma; Transfusion.

Copyright © 2015 Elsevier Masson SAS. All rights reserved.

References

    1. Finegold I., Dockhorn R.J., Ein D., Dolen W.K., Oppenheimer J., Potter L.H. Immunotherapy throughout the decades: from noon to now. Ann Allergy Asthma Immunol. 2010;105:328–337.
    1. Shahani L., Singh S., Khardori N.M. Immunotherapy in clinical medicine: historical perspective and current status. Med Clin N Am. 2012;96:421–431.
    1. Shakir E.M., Cheung D.S., Grayson M.H. Mechanisms of immunotherapy: a historical perspective. Ann Allergy Asthma Immunol. 2010;105:340–347.
    1. Graham B.S., Ambrosino D.M. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10:129–134.
    1. Rambar A.C. Convalescent serum and pooled plasma in communicable diseases. US Nav Med Bull. 1946;46:93–96.
    1. Kak V., Sundareshan V., Modi J., Khardori N.M. Immunotherapies in infectious diseases. Med Clin N Am. 2012;96:455–474.
    1. Hsu J., Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect Dis Clin N Am. 2011;25:773–788.
    1. Lachman P.J. The use of antibodies in the prophylaxis and treatment of infections. Emerg Microbes Infect. 2012;1 e-11.
    1. Finegold I., Oppenheimer J. Immunotherapy: the next 100 years. Ann Allergy Asthma Immunol. 2010;105:394–398.
    1. Mahanty S., Garraud O. Emerging and re-emerging pathogens: immunological aspects of viral hemorrhagic fevers. In: Garraud O., editor. Tropical Immunology. Research Signpost; Trivandrum (India): 2005. pp. 99–116.
    1. Peigue-Lafeuille H., Bourhy H., Abiteboul D., Astoul J., Cliquet F., Goudal M. La rage humaine en France en 2004 : état des lieux et prise en charge. Med Mal Infect. 2004;34:551–560.
    1. Couderc T., Khandoudi N., Grandadam M., Visse C., Gangneux N., Bagot S. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200:516–523.
    1. Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A. 1994;91:10198–10202.
    1. McHardy N. Passive protection of mice against infection with Trypanosoma cruzi with plasma: the use of blood- and vector-bug derived trypomastogote challenge. Parasitology. 1980;80:471–478.
    1. Avenard G., Gaiffe M., Herzog F. Prévention de la varicelle chez les enfants à haut risque. Efficacité comparée des immunoglobulines spécifiques et du plasma défibriné de convalescent (414 cas) Nouv Presse Med. 1979;8:673–775.
    1. Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L., Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Int Med. 2006;145:599–610.
    1. Zingher A., Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles. Rev Med Virol. 2005;15:407–421.
    1. Young M.K., Nimmo G.R., Cripps A.W., Jones M.A. Post-exposure passive immunization for preventing measles. Cochrane Database Syst Rev. 2014;4:CD010056.
    1. Jahrling P.B., Peters C.J. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun. 1984;44:528–533.
    1. Frame J.D., Verbrugge G.P., Gill R.G., Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 1984;78:319–324.
    1. McCormick J.B., King I.J., Webb P.A., Schribner C.L., Craven R.B., Johnson K.M. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20–26.
    1. Jahrling P.B., Frame J.D., Rhoderick J.B., Monson M.H. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Med Hyg. 1985;79:380–384.
    1. Gouwen B.B., Bray M. Progress in the experimentally therapy of severe arenaviral infections. Future Microbiol. 2011;6:1429–1430.
    1. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 1996;6:285–297.
    1. Ye C., Prescott J., Nofchissey R., Goade D., Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from Hantavirus cardiopulmonary syndrome. Emerg Infect Dis. 2004;10:478–482.
    1. Klingström J., Stolz M., Hardestam J., Ahlm C., Lundkvist A. Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge. Antivir Ther. 2008;13:125–133.
    1. Shayan S., Bokaean M., Shavrivar M.R., Chinikar S. Crimean-Congo hemorrhagic fever. Lab Med. 2015;46:180–189.
    1. Heshmati F. Vol. 7. Mémoire pour le diplôme universitaire d’infection à VIH et SIDA en France et dans le Monde; Paris: 1992. (Méthodologie de l’immunothérapie passive et étude de l’évolution clinique et biologique de sujets séropositifs VIH-1 asymptomatiques au décours de dons répétés en plasmaphérèse).
    1. Lefrère J.J., Roudot-Thoraval F., Vittecoq D., Heshmati F., Audat F., Lerable J. Quantitation of passively acquired human immunodeficiency virus (HIV) antibodies in AIDS patients transfused with a plasma rich in HIV antibodies. Transfusion. 1996;36:734–738.
    1. Morand-Joubert L., Vittecoq D., Roudot-Thoraval F., Mariotti M., Lefrère F., Heshmati F. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies. Vox Sang. 1997;73:149–154.
    1. Lefrère J.J., Vittecoq D., Mattlinger B., Boulard G., de Bruyn B., Courroucé A.M. Immunothérapie passive dans le SIDA : transfusion de plasma riche en anticorps anti-p25 (essai de phase I) Rev Fr Transfus Hemobiol. 1991;34:199–211.
    1. Yeh K.M., Chiueh T.Z., Siu L.K., Lin J.C., Chan P.K.S., Peng M.Y. Experience using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–922.
    1. Wong V.W.S., Dai D., Wu A.K.L., Sung J.J.Y. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003;9:199–201.
    1. Zhang Z., Xie Y.W., Hong J., Zhang X., Kwok S.Y., Huang X. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion. 2005;45:1160–1164.
    1. Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H. Use of convalescent plasma therapy in SARS patients in Hong-Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
    1. Soo Y.O., Cheng Y., Wong R., Hui D.S., Tsang K.K., Ng M.H. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676–678.
    1. Wong S.S.W., Yuen K.Y. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008;62:437–441.
    1. Stockman L.J., Bellamy R., Garner P., SARS: SARS: systematic review of treatment effects. PloS Med. 2006;3:e343.
    1. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., Cleary P., Khaw F.M., Lim W.S. The effectiveness of convalescent plasma and hyperimmune immunolobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.
    1. Hui D.S. Severe acute respiratory syndrome (SARS): lessons learnt in Hong-Kong. J Thorac Dis. 2013;5:S122–S126.
    1. Zhou B., Zhong N., Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450–1451.
    1. Kong L.K. Successful treatment of avian influenza with convalescent plasma (Letter) Hong Kong Med J. 2006;12:489.
    1. Hui D.S., Lee N., Chan P.K. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res. 2013;98:410–416.
    1. Luke T.C., Casadevall A., Watocich S.J., Hoffman S.L., Beigel J.H., Burgess T.H. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38:e66–e73.
    1. Beigel J.H., Luke T.C. A study in scarlet: convalescent plasma for severe influenza. Crit Care Med. 2012;40:1027–1028.
    1. Hohenadl C., Wodal W., Kerschbaum A., Fritz R., Howard M.K., Farcet M.R. Hyperimmune intravenous immunoglobulins containing high titres of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice. Virol J. 2014;11:70.
    1. Ortiz J.R., Rudd K.E., Clark D.V., Jacob S.T., West T.E. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Crit Care Med. 2013;41:1345–1352.
    1. Hung I.F.N., To K.K.W., Lee C.K., Lee K.L., Chan K., Yan W.W. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456.
    1. Wong H.K., Cheuk K.L., Hung I.F.N., Leung J.N.S., Hong J., Yuen K.Y. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50:1967–1971.
    1. Kreil T.R., Shau-Ping Lei L., Camacho L., Wodal W., Kerschbaum A., Segura E. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion. 2012;52:803–809.
    1. Parry R.P., Tettmar K.L., Hoschler K., Brailsford S.R., Samuel D., Ashford A. Strategies for screening blood donors to source convalescent H1N1 v plasma for intervention therapy. Vox Sang. 2012;103:107–112.
    1. Wu P., Cowling B.J., Wu J.T., Lau E.H.Y., Ip D.K.M., Nishiura H. The epidemiological and public health research response to 2009 pandemic influenza (H1N1): experiences from Hong-Kong. Influenza Other Respir Viruses. 2013;7:367–382.
    1. Hung I.F.N., To K.K.W., Lee C.K., Lee K.L., Yan W.W., Chan K. Hyperimmune IV immunoglobulin treatment. A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–473.
    1. Gupta M., Mahanty S., Bray M., Rollin P.E. Passive transfer of antibodies protect immunocompetent and immunodeficient mice against letal Ebola virus infection without complete inhibition of viral replication. J Virol. 2001;75:4649–4654.
    1. Colebunders R.L., Cannon R.O. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis. 2015;211:1208–1210.
    1. Gutfraind A., Meyers L.A. Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis. 2015;211:1262–1267.
    1. van Griensven J., de Weiggheleire A., Delamou A., Smith P.G., Vandekerckhove P., Bah E.I. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2015 pii: civ680. [Epub ahead of print]
    1. Lu S. Using convalescent whole blood of plasma as passive immune therapy for global war against Ebola. Emerg Microbes Infect. 2014;3:e80.
    1. Garraud O., World Apheresis Association Board World Apheresis Association letter to the WHO: the World Apheresis Association urges the development of preparedness plans to make specific plasma available when urgently needed. Transfus Apher Sci. 2014;51:2–3.
    1. Burnouf T., Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120–125.
    1. Burnouf T., Emmanuel J., Mbanya D., El-Ekiaby M., Murphy W., Field S. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet. 2014;384:1347–1348.
    1. Kraft C.S., Hewlett A.L., Koepsell S., Winkler A.M., Kratochvil C.J., Larson L.A. The use of TKM-100802 a convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61:496–502.
    1. Abela I.A., Reynell L., Trkola A. Therapeutic antibodies in HIV treatment: classical approaches to novel advances. Curr Pharm Des. 2010;16:3754–3766.
    1. Flingai S., Plummer E.M., Patel A., Shresta S., Mendoza J.M., Broderick K.E. Protection against dengue disease by synthetic nucleic acid antibody therapy. Sci Rep. 2015;5:12616.
    1. Martina B.E. Dengue pathogenesis: a disease driven by the host response. Sci Prog. 2014;97:197–214.
    1. Brailsford S.R., Kelly D., Kohli H., Slowther A., Watkins N.A. Blood Donor Selection Steering Group of the Advisory Committee for the Safety of Blood, Tissues, Organs. Who should donate blood? Policy decisions on donor deferral criteria should protect recipients and be fair to donors. Transfus Med. 2015;25:234–238.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj